Financial Ratios Smith & Nephew Plc
Stocks
SN.
GB0009223206
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,119.00 GBX | -1.67% |
|
+0.36% | -9.73% |
| 07-16 | MedTech facing a three-front squeeze | ![]() |
| 07-15 | Smith+Nephew Launches Lynx Coblation Laryngeal Wand for Ent Surgeons | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.06 | 3.91 | 4.62 | 5.44 | 5.27 | |||||
Return on Total Capital | 4.98 | 4.79 | 5.61 | 6.56 | 6.37 | |||||
Return On Equity % | 9.66 | 4.12 | 5.02 | 7.86 | 11.84 | |||||
Return on Common Equity | 9.66 | 4.12 | 5.02 | 7.86 | 11.84 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 70.95 | 70.85 | 70.14 | 70.21 | 68.25 | |||||
SG&A Margin | 50.59 | 51.91 | 51.07 | 49.98 | 49.25 | |||||
EBITDA Margin % | 22.6 | 21.13 | 21.14 | 22.98 | 21.67 | |||||
EBITA Margin % | 17.4 | 16.09 | 16.6 | 18.31 | 17.05 | |||||
EBIT Margin % | 13.66 | 12.52 | 13.3 | 15.25 | 14.23 | |||||
Income From Continuing Operations Margin % | 10.05 | 4.28 | 4.74 | 7.09 | 10.14 | |||||
Net Income Margin % | 10.05 | 4.28 | 4.74 | 7.09 | 10.14 | |||||
Net Avail. For Common Margin % | 10.05 | 4.28 | 4.74 | 7.09 | 10.14 | |||||
Normalized Net Income Margin | 7.69 | 5.36 | 6.87 | 7.86 | 8.8 | |||||
Levered Free Cash Flow Margin | 12.45 | 2.51 | 4.45 | 9.73 | 14.22 | |||||
Unlevered Free Cash Flow Margin | 13.41 | 3.47 | 5.93 | 11.29 | 15.64 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.48 | 0.5 | 0.56 | 0.57 | 0.59 | |||||
Fixed Assets Turnover | 3.52 | 3.51 | 3.79 | 4.02 | 4.03 | |||||
Receivables Turnover (Average Receivables) | 5.54 | 5.22 | 5.32 | 5.49 | 5.57 | |||||
Inventory Turnover (Average Inventory) | 0.86 | 0.75 | 0.72 | 0.72 | 0.87 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.08 | 2.25 | 1.77 | 2.89 | 2.57 | |||||
Quick Ratio | 1.16 | 0.89 | 0.67 | 1.21 | 1.17 | |||||
Operating Cash Flow to Current Liabilities | 0.41 | 0.27 | 0.27 | 0.64 | 0.81 | |||||
Days Sales Outstanding (Average Receivables) | 65.9 | 69.92 | 68.61 | 66.71 | 65.58 | |||||
Days Outstanding Inventory (Average Inventory) | 426.11 | 486.15 | 506.64 | 505.55 | 420.02 | |||||
Average Days Payable Outstanding | 211.73 | 201.03 | 202.06 | 222.83 | 242.54 | |||||
Cash Conversion Cycle (Average Days) | 280.28 | 355.04 | 373.18 | 349.43 | 243.06 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 59.97 | 54.61 | 59.11 | 63.08 | 62.9 | |||||
Total Debt / Total Capital | 37.49 | 35.32 | 37.15 | 38.68 | 38.61 | |||||
LT Debt/Equity | 51.15 | 51.57 | 44.45 | 61.88 | 60.07 | |||||
Long-Term Debt / Total Capital | 31.97 | 33.35 | 27.94 | 37.95 | 36.87 | |||||
Total Liabilities / Total Assets | 49.01 | 47.23 | 47.76 | 49.15 | 49.42 | |||||
EBIT / Interest Expense | 8.9 | 8.16 | 5.59 | 6.11 | 6.26 | |||||
EBITDA / Interest Expense | 15.42 | 14.48 | 9.3 | 9.58 | 9.89 | |||||
(EBITDA - Capex) / Interest Expense | 10.32 | 10 | 6.06 | 6.95 | 6.8 | |||||
Total Debt / EBITDA | 2.71 | 2.48 | 2.51 | 2.39 | 2.4 | |||||
Net Debt / EBITDA | 1.66 | 2.18 | 2.27 | 1.95 | 2 | |||||
Total Debt / (EBITDA - Capex) | 4.04 | 3.59 | 3.86 | 3.29 | 3.49 | |||||
Net Debt / (EBITDA - Capex) | 2.48 | 3.15 | 3.48 | 2.68 | 2.91 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 14.3 | 0.06 | 6.4 | 4.7 | 6.09 | |||||
Gross Profit, 1 Yr. Growth % | 16.33 | -0.08 | 5.33 | 4.72 | 3.14 | |||||
EBITDA, 1 Yr. Growth % | 33.41 | -6.45 | 6.44 | 13.52 | 0.07 | |||||
EBITA, 1 Yr. Growth % | 45.59 | -7.5 | 9.77 | 15.15 | -1.22 | |||||
EBIT, 1 Yr. Growth % | 64.43 | -8.29 | 13.02 | 19.57 | -1.02 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 16.96 | -57.44 | 17.94 | 56.65 | 51.7 | |||||
Net Income, 1 Yr. Growth % | 16.96 | -57.44 | 17.94 | 56.65 | 51.7 | |||||
Normalized Net Income, 1 Yr. Growth % | 65.21 | -30.27 | 36.47 | 20.43 | 18.74 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 16.6 | -57.29 | 18.04 | 56.15 | 52.34 | |||||
Accounts Receivable, 1 Yr. Growth % | 6.59 | 5.77 | 3.12 | 0 | 9.16 | |||||
Inventory, 1 Yr. Growth % | 9.05 | 19.58 | 8.62 | -0.33 | -11.31 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 4.42 | -3.83 | 1.03 | -3.27 | 15.19 | |||||
Total Assets, 1 Yr. Growth % | -0.84 | -8.74 | 0.21 | 3.67 | 0.99 | |||||
Tangible Book Value, 1 Yr. Growth % | 36.53 | -16 | 12.4 | 8.25 | 7.62 | |||||
Common Equity, 1 Yr. Growth % | 5.47 | -5.55 | -0.8 | 0.92 | 0.46 | |||||
Cash From Operations, 1 Yr. Growth % | -6.2 | -46.64 | 29.91 | 62.34 | 30.19 | |||||
Capital Expenditures, 1 Yr. Growth % | -7.9 | -12.26 | 19.27 | -10.77 | 13.65 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 150.7 | -79.8 | 88.18 | 127.3 | 55.12 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 134.86 | -74.09 | 81.78 | 98.04 | 47.03 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 0 | 0 | 0 | 4.27 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 0.72 | 6.94 | 3.18 | 5.55 | 5.4 | |||||
Gross Profit, 2 Yr. CAGR % | -1.44 | 7.81 | 2.59 | 5 | 3.93 | |||||
EBITDA, 2 Yr. CAGR % | -9.14 | 9.03 | -1.9 | 7.74 | 4.9 | |||||
EBITA, 2 Yr. CAGR % | -12.51 | 12.15 | -1.49 | 9.52 | 4.52 | |||||
EBIT, 2 Yr. CAGR % | -14.81 | 22.8 | 1.81 | 16.04 | 8.79 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -6.55 | -29.45 | -29.15 | 35.92 | 54.16 | |||||
Net Income, 2 Yr. CAGR % | -6.55 | -29.45 | -29.15 | 35.92 | 54.16 | |||||
Normalized Net Income, 2 Yr. CAGR % | -16.35 | 7.33 | -2.45 | 28.17 | 19.58 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -6.58 | -29.43 | -28.99 | 35.76 | 54.23 | |||||
Accounts Receivable, 2 Yr. CAGR % | -5.27 | 6.18 | 4.43 | 1.55 | 4.48 | |||||
Inventory, 2 Yr. CAGR % | 6.89 | 14.19 | 13.97 | 4.05 | -5.98 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 6.94 | 0.21 | -1.43 | -1.14 | 5.56 | |||||
Total Assets, 2 Yr. CAGR % | 8.37 | -4.87 | -4.37 | 1.93 | 2.33 | |||||
Tangible Book Value, 2 Yr. CAGR % | 22.66 | 7.09 | -2.83 | 10.31 | 7.94 | |||||
Common Equity, 2 Yr. CAGR % | 4.07 | -0.19 | -3.2 | 0.06 | 0.69 | |||||
Cash From Operations, 2 Yr. CAGR % | -13.35 | -29.25 | -16.74 | 45.22 | 45.38 | |||||
Capital Expenditures, 2 Yr. CAGR % | 0 | -10.1 | 2.3 | 3.16 | 0.7 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -0.57 | -28.83 | -38.29 | 105.17 | 87.77 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 0.13 | -21.99 | -31.32 | 88.65 | 70.64 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 0 | 0 | 0 | 2.11 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 2.05 | 0.5 | 6.76 | 3.69 | 5.73 | |||||
Gross Profit, 3 Yr. CAGR % | 0.84 | -0.99 | 6.98 | 3.32 | 4.37 | |||||
EBITDA, 3 Yr. CAGR % | -5.66 | -8.25 | 8.16 | 3.08 | 5.12 | |||||
EBITA, 3 Yr. CAGR % | -7.66 | -10.87 | 11.36 | 3.89 | 5.82 | |||||
EBIT, 3 Yr. CAGR % | -9.98 | -12.69 | 19.45 | 7.56 | 10.05 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -7.54 | -28.1 | -16.27 | -7.7 | 40.99 | |||||
Net Income, 3 Yr. CAGR % | -7.54 | -28.1 | -16.27 | -7.7 | 40.99 | |||||
Normalized Net Income, 3 Yr. CAGR % | -10.6 | -21.27 | 16.28 | 4.48 | 24.95 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -7.61 | -28.03 | -16.23 | -7.66 | 41.08 | |||||
Accounts Receivable, 3 Yr. CAGR % | -4.19 | -1.72 | 5.15 | 2.93 | 4.02 | |||||
Inventory, 3 Yr. CAGR % | 9.75 | 10.96 | 12.3 | 8.98 | -1.35 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 12.52 | 3.22 | 0.48 | -2.05 | 4.03 | |||||
Total Assets, 3 Yr. CAGR % | 10.66 | 2.34 | -3.2 | -1.76 | 1.62 | |||||
Tangible Book Value, 3 Yr. CAGR % | -3.81 | 8.11 | 8.83 | 0.73 | 9.4 | |||||
Common Equity, 3 Yr. CAGR % | 4.54 | 0.76 | -0.39 | -1.85 | 0.19 | |||||
Cash From Operations, 3 Yr. CAGR % | -1.97 | -26.28 | -13.36 | 4.02 | 40.03 | |||||
Capital Expenditures, 3 Yr. CAGR % | 5.55 | -4.26 | -1.22 | -2.26 | 6.55 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 7.73 | -41.55 | -1.59 | -4.46 | 86.91 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 7.93 | -36.19 | 3.42 | -2.06 | 73.61 | |||||
Dividend Per Share, 3 Yr. CAGR % | 1.37 | 0 | 0 | 0 | 1.4 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 2.22 | 1.82 | 2.5 | 2.49 | 6.21 | |||||
Gross Profit, 5 Yr. CAGR % | 1.71 | 0.99 | 1.54 | 1.39 | 5.76 | |||||
EBITDA, 5 Yr. CAGR % | -2.35 | -3.4 | -3.52 | -1.32 | 7.58 | |||||
EBITA, 5 Yr. CAGR % | -3.84 | -4.69 | -4.38 | -2.13 | 9.52 | |||||
EBIT, 5 Yr. CAGR % | -4.83 | -5.68 | -5.44 | -2.02 | 15.16 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -7.74 | -21.89 | -16.88 | -7.24 | 6.89 | |||||
Net Income, 5 Yr. CAGR % | -7.74 | -21.89 | -16.88 | -7.24 | 6.89 | |||||
Normalized Net Income, 5 Yr. CAGR % | -5.58 | -11.54 | -7.42 | -4.41 | 17.47 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -7.42 | -21.89 | -16.84 | -7.23 | 6.94 | |||||
Accounts Receivable, 5 Yr. CAGR % | -0.35 | -0.56 | -0.83 | -0.43 | 4.88 | |||||
Inventory, 5 Yr. CAGR % | 8.19 | 11.08 | 11.42 | 8.14 | 4.6 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 9.03 | 6.76 | 6.72 | 1.45 | 2.48 | |||||
Total Assets, 5 Yr. CAGR % | 8.26 | 4.85 | 4.38 | 2.17 | -1.03 | |||||
Tangible Book Value, 5 Yr. CAGR % | 26.89 | 1.92 | -3.42 | 8.99 | 8.47 | |||||
Common Equity, 5 Yr. CAGR % | 7.06 | 2.52 | 1.37 | 0.48 | 0.04 | |||||
Cash From Operations, 5 Yr. CAGR % | 0.65 | -15.56 | -8.17 | -3.31 | 6.57 | |||||
Capital Expenditures, 5 Yr. CAGR % | 4.98 | -0.98 | 4.24 | -1.36 | -0.46 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 6.42 | -24.21 | -13.82 | -2.95 | 27.63 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 6.59 | -20.2 | -9.95 | -1.22 | 26.5 | |||||
Dividend Per Share, 5 Yr. CAGR % | 4.02 | 1.39 | 0.82 | 0 | 0.84 |
- Stock Market
- Stocks
- SN. Stock
- Financials Smith & Nephew Plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
















